MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

Strona główna・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

6.87 1.18

Buy Sell

Overview

Share price change

24h

Current

Min

6.72

Max

7.06

Key metrics
By Trading Economics
Income	7.8M 13M
Sales	-4M 159M
Profit margin	8.092
Employees	580
EBITDA	3.7M 32M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+191.61% upside

Dividends
By Dow Jones
Next Earnings	23 lut 2026

Market Stats
By TradingEconomics
Market Cap	-135M 1.4B
Previous open	5.69
Previous close	6.87

News Sentiment

By Acuity

50%

141 / 352 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 sty 2026, 23:49 UTC

Hot Stocks

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26 sty 2026, 23:09 UTC

Major Market Movers

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26 sty 2026, 23:52 UTC

Market Talk

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26 sty 2026, 23:46 UTC

Market Talk

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26 sty 2026, 23:37 UTC

Market Talk

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26 sty 2026, 22:41 UTC

Market Talk

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26 sty 2026, 22:26 UTC

Earnings

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26 sty 2026, 22:26 UTC

Earnings

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26 sty 2026, 22:25 UTC

Earnings

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26 sty 2026, 22:25 UTC

Earnings

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26 sty 2026, 22:25 UTC

Earnings

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26 sty 2026, 22:24 UTC

Earnings

Karoon Energy 4Q Sales Revenue US$156.1 Million

26 sty 2026, 22:23 UTC

Earnings

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26 sty 2026, 22:23 UTC

Earnings

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26 sty 2026, 22:23 UTC

Earnings

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26 sty 2026, 22:22 UTC

Earnings

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26 sty 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Copper Shareholders Approve Takeover

26 sty 2026, 22:02 UTC

Acquisitions, Mergers, Takeovers

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26 sty 2026, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

26 sty 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 sty 2026, 21:34 UTC

Earnings

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26 sty 2026, 21:34 UTC

Earnings

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26 sty 2026, 21:34 UTC

Earnings

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26 sty 2026, 21:34 UTC

Earnings

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26 sty 2026, 21:30 UTC

Earnings

Nucor 4Q Sales $7.69B >NUE

26 sty 2026, 21:30 UTC

Earnings

Nucor 4Q Net $378M >NUE

26 sty 2026, 21:30 UTC

Earnings

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26 sty 2026, 21:30 UTC

Earnings

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26 sty 2026, 21:30 UTC

Earnings

Nucor 4Q EPS $1.64 >NUE

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

191.61% upside

12 Months Forecast

Average 19.8 USD 191.61%

High 32 USD

Low 8 USD

Based on 10 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

141 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.